EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals

Cassia Leal iD, Jorge Strogoff-de-Matos, Carmem Theodoro iD, Rosangela Teixeira, Renata Perez iD, Thais Guaraná, Paulo de Tarso Pinto, Tatiana Guimarães, Solange Artimos iD

Viruses · 2023

DOI: 10.3390/v15010221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Cassia Leal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Unit, Internal Medicine Department, Hospital Federal dos Servidores do Estado, Rio de Janeiro 20221-161, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis C, Chronic, Liver Neoplasms, Hepatitis C. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Conflicting data regarding the incidence of hepatocellular carcinoma (HCC) after cure of HCV infection with direct-acting antivirals (DAAs) remains. We investigated the incidence and risk factors to HCC after treatment with DAAs followed up for five years.

Methods

A total of 1075 HCV patients ≥ 18 years were treated with DAAs from 2015 to 2019 and followed until 2022. Ultrasonography was performed before DAAs and each 6 months thereafter.

Results

Of the total, 51/1075 (4.7%) developed HCC in the median of 40 (IQR 25–58) months: 26/51 (51%) male, median age 60 (IQR 54–66) years, alpha-fetoprotein (AFP) 12.2 (IQR 6.1–18.8) ng/mL, 47/51 (92.1%) cirrhotic 78.7%, 8/51 (15.7%) without sustained virological response (SVR). Seventeen percent had non-characterized nodules before DAAs. Cumulative HCC incidence was 5.9% in 5 years. Overall incidence was 1.46/100 patient-years (PY) (95% CI = 1.09–1.91), being 2.31/100 PY (95% CI = 1.70–3.06), 0.45/100 PY (95% CI = 0.09–1.32) and 0.20/100 PY (95% CI 0.01–1.01) in METAVIR F4, F3 and F2, respectively, and the main risks to HCC were non-characterized nodule, cirrhosis, high AFP values and non-SVR.

Conclusion

HCV cure reduced risk for HCC, but it still occurred particularly in cirrhotic patients. Some risk factors can be identified to predict early HCC diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHepatitis C, ChronicLiver NeoplasmsHepatitis CHumansMaleMiddle AgedFemaleAntiviral Agentsalpha-FetoproteinsIncidenceRisk FactorsLiver Cirrhosis

Stichwörter der Autor:innen

direct-acting antiviralshepatitis C treatmenthepatocellular carcinomaincidence

Substanzen

Antiviral Agentsalpha-Fetoproteins

Autor:innen und Institutionen

  • Gastroenterology and Hepatology Unit, Internal Medicine Department, Hospital Federal dos Servidores do Estado, Rio de Janeiro 20221-161, Brazil.
  • Gastroenterology and Hepatology Unit, Antônio Pedro Universitary Hospital, Fluminense Federal University, Rio de Janeiro 24033-900, Brazil.
  • Departamento de Medicina Clínica, Faculdade de Medicina, Universidade Federal Fluminense, Rio de Janeiro 24033-900, Brazil.
  • Departamento de Clínica Médica, Faculdade de Medicina, Instituto Alfa de Gastroenterologia Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil.
  • Hospital Felício Rocho, Belo Horizonte 30110-934, Brazil.
  • Hepatology Division, D'Or Institute for Research and Education (IDOR), Rio de Janeiro 22281-100, Brazil.

ORCID-Profile: Cassia Leal, Carmem Theodoro, Renata Perez, Solange Artimos

Zitieren

APA

Leal, C., Strogoff-de-Matos, J., Theodoro, C., Teixeira, R., Perez, R., Guaraná, T., de Tarso Pinto, P., Guimarães, T., & Artimos, S. (2023). Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals. Viruses. https://doi.org/10.3390/v15010221

Vancouver

Leal C, Strogoff-de-Matos J, Theodoro C, Teixeira R, Perez R, Guaraná T, et al. Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals. Viruses. 2023. doi:10.3390/v15010221

BibTeX
@article{Leal2023,
  author = {Leal, Cassia and Strogoff-de-Matos, Jorge and Theodoro, Carmem and Teixeira, Rosangela and Perez, Renata and Guaraná, Thais and de Tarso Pinto, Paulo and Guimarães, Tatiana and Artimos, Solange},
  title = {Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15010221}
}
Kostenlos starten →